Pathologic complete response with radiation and vismodegib in a patient with advanced basal cell carcinoma: A case report

Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Cordova M, Nehal KS and Rossi A: Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 80:303–317. 2019.PubMed/NCBI View Article : Google Scholar

Likhacheva A, Awan M, Barker CA, Bhatnagar A, Bradfield L, Brady MS, Buzurovic I, Geiger JL, Parvathaneni U, Zaky S and Devlin PM: Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: Executive summary of an American society for radiation oncology clinical practice guideline. Pract Radiat Oncol. 10:8–20. 2020.PubMed/NCBI View Article : Google Scholar

Wilder RB, Kittelson JM and Shimm DS: Basal cell carcinoma treated with radiation therapy. Cancer. 68:2134–2137. 1991.PubMed/NCBI View Article : Google Scholar

Armstrong P, Martin S and Lask G: Sonic hedgehog pathway inhibition in the treatment of advanced basal cell carcinoma. In: Biologic and Systemic Agents in Dermatology. Springer, Cham, pp541-548, 2018.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, et al: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 366:2171–2179. 2012.PubMed/NCBI View Article : Google Scholar

Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, et al: Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 72:1021–1026.e8. 2015.PubMed/NCBI View Article : Google Scholar

Hehlgans S, Booms P, Güllülü Ö, Sader R, Rödel C, Balermpas P, Rödel F and Ghanaati S: Radiation sensitization of basal cell and head and neck squamous cell carcinoma by the hedgehog pathway inhibitor vismodegib. Int J Mol Sci. 19(2485)2018.PubMed/NCBI View Article : Google Scholar

Franco AI, Eastwick G, Farah R, Heyboer M, Lee M and Aridgides P: Upfront radiotherapy with concurrent and adjuvant vismodegib is effective and well-tolerated in a patient with advanced, multifocal basal cell carcinoma. Case Rep Dermatol Med. 2018(2354146)2018.PubMed/NCBI View Article : Google Scholar

Pollom EL, Bui TT, Chang AL, Colevas AD and Hara WY: Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma. JAMA Dermatol. 151:998–1001. 2015.PubMed/NCBI View Article : Google Scholar

Block AM, Alite F, Diaz AZ, Borrowdale RW, Clark JI and Choi M: Combination trimodality therapy using vismodegib for basal cell carcinoma of the face. Case Rep Oncol Med. 2015(827608)2015.PubMed/NCBI View Article : Google Scholar

Gathings RM, Orscheln CS and Huang WW: Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin. J Am Acad Dermatol. 70:e88–e89. 2014.PubMed/NCBI View Article : Google Scholar

Zeng J, Aziz K, Chettiar ST, Aftab BT, Armour M, Gajula R, Gandhi N, Salih T, Herman JM, Wong J, et al: Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. Int J Radiat Oncol Biol Phys. 86:143–149. 2013.PubMed/NCBI View Article : Google Scholar

Le H, Kleinerman R, Lerman OZ, Brown D, Galiano R, Gurtner GC, Warren SM, Levine JP and Saadeh PB: Hedgehog signaling is essential for normal wound healing. Wound Repair Regen. 16:768–773. 2008.PubMed/NCBI View Article : Google Scholar

ClinicalTrials.gov: Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma. ClinicalTrials.gov Identifier: NCT01835626. https://clinicaltrials.gov/ct2/show/NCT01835626. Last updated October 5, 2020.